What Ketasol-100 Treats: Main Uses and Benefits

Ketasol-100 is applied in clinical settings across several key domains where rapid, reliable symptom control and patient stabilization are essential. It is fundamentally used to manage overwhelming symptoms, particularly those related to pain and consciousness, allowing for necessary medical interventions. The drug is utilized in symptomatic management and procedural sedation.

The medication is commonly used to help with easing the burden of severe pain in acute settings, facilitating controlled unawareness for necessary procedures, and supporting symptom management in critically ill patients. It is also applied in managing symptoms linked to airway constriction, such as acute bronchospasm. This quick symptomatic relief may assist with maintaining functional stability and contributes to easing the overall symptom load on the patient during periods of heightened symptoms.

“Ketasol-100 is applied with the intention to provide supportive relief that helps patients cope more steadily with difficult episodes of pain and distress.”

Quick Fact	Supportive Management for Symptom
Primary Benefit	Severe Pain and Physical Discomfort
Supportive Benefit	Symptoms related to Systemic Imbalance
Procedural Use	Unawareness during Necessary Interventions

Regulatory References

1. NCBI StatPearls Overview

Who Can and Cannot Use Ketasol-100: Official Regulatory Information

The eligibility profile for Ketasol-100 (Ketamine Hydrochloride) is strictly defined by government regulatory documents, focusing on patient safety related to cardiovascular health and pre-existing conditions.

Absolute Contraindications

Ketasol-100 is contraindicated and must not be used in patients with known hypersensitivity to the drug or any component, or for those in whom a significant elevation of blood pressure would constitute a serious hazard. This includes individuals with pre-existing conditions such as severe hypertension, severe coronary or myocardial disease, eclampsia or pre-eclampsia, or a history of cerebrovascular accident (stroke).

Restrictions and Special Considerations

Use is restricted and requires caution in several populations. Patients with liver impairment (e.g., cirrhosis), psychiatric illness (e.g., schizophrenia, acute psychosis), or conditions that increase intracranial or intraocular pressure (e.g., glaucoma) should only use the medicine under strictly monitored conditions.

Population Group	Eligibility Status (Regulatory Wording)
Pediatric (≤ 3 years)	Restricted; Warning regarding potential Pediatric Neurotoxicity following prolonged or repeated use.
Pregnancy/Lactation	Not Recommended; Safe use has not been established in these human populations.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ketasol-100 primarily through two types of interactions: pharmacodynamic enhancement and pharmacokinetic alteration.

Co-administration with other Central Nervous System (CNS) depressants, including Opioid Analgesics, Benzodiazepines, Barbiturates, and Alcohol (Ethanol), may result in documented profound sedation and respiratory depression. The combination with Sympathomimetics and Vasopressin may conversely enhance the sympathomimetic effects of the product, leading to potential increases in blood pressure, while Thyroid Hormones increase the risk of documented hypertension and tachycardia.

---

Pharmacokinetic and Restriction Rules

Interaction Type	Interacting Product(s)	Official Outcome/Restriction
Formal Contraindication	Theophylline, Aminophylline	Advised against due to risk of lowering the seizure threshold
PK Alteration (CYP3A4 Inducers)	Rifampin, St. John’s Wort	Decrease plasma concentrations, potentially reducing efficacy
PK Alteration (CYP3A4 Inhibitors)	Grapefruit Juice	May lead to an increase in plasma concentrations
Chemical Incompatibility	Barbiturates, Diazepam	Must not be mixed in the same syringe or infusion fluid

Co-use requires caution for chronic alcoholic or acutely alcohol-intoxicated patients due to the heightened risk of CNS depressant effects, as noted in the product labeling.

Ketasol-100 functions as a selective inhibitor of the enzyme cyclooxygenase-2 (COX-2), which is constitutively upregulated in response to cell injury and specific physiological triggers. Ketasol-100 selectively binds to the hydrophobic channel of the COX-2 active site. This interaction effectively antagonizes the enzyme's capacity to catalyze the conversion of arachidonic acid into prostaglandin intermediates.

This specific molecular interference results in a reduction in the biosynthesis of pro-inflammatory prostaglandins (e.g., PGE2). By modifying the local concentration of these lipid mediators, Ketasol-100 modulates downstream inflammatory signaling cascades within affected tissues. Furthermore, this mechanism has been observed to affect cellular signaling pathways integral to osteoclastogenesis, a process involving the differentiation and activity of bone-resorbing cells. The final pharmacodynamic effect is the modification of cellular response to inflammatory and remodeling stimuli, strictly at the physiological system level, without reference to clinical outcomes.

How to Use Ketasol-100: Official Administration Guidelines

Ketasol-100 is administered only by a healthcare professional via injection into a vein (intravenous, or IV) or into a muscle (intramuscular, or IM). The specific dose is highly individualized based on the patient's body weight, age, and medical procedure requirements, and is adjusted according to the patient's observed needs.

---

Administration Details

Administration Aspect	Official Instruction
Route of Administration	Intravenous (IV) or Intramuscular (IM) injection.
IV Administration Speed	IV doses must be administered slowly over a period of 60 seconds.
Dose Titration	The amount given is titrated (adjusted) to achieve the desired clinical effect and is not a fixed quantity.
Dilution for IV Use	The highly concentrated 100 mg/mL vial must be diluted prior to IV administration. It is mixed with an equal volume of a compatible solution, such as Sterile Water, 0.9% Sodium Chloride, or 5% Dextrose in Water.
Concentration for Infusion	For continuous IV maintenance, the medicine is further diluted to concentrations such as 1 mg/mL or 2 mg/mL in a large-volume IV solution.

---

Official Dosing Rules

• IV Induction Dose: The initial dose for injection into a vein is typically in the range of 1 mg/kg to 4.5 mg/kg.
• IM Induction Dose: The initial dose for injection into a muscle is higher, typically ranging from 6.5 mg/kg to 13 mg/kg.
• Maintenance: Additional doses (usually one-half to the full initial dose) are given as necessary to sustain the effect, or a slow, continuous infusion may be started.

These protocols ensure that Ketasol-100 is prepared and delivered according to established standardized procedures, emphasizing controlled administration speed and dose adjustment.

Ketasol-100: Recent Clinical Evidence

Clinical research surrounding Ketasol-100 has focused primarily on its potential applications in chronic pain and anxiety management. Studies are designed to rigorously assess the observed effects of the compound.

---

Chronic Pain and Neuropathic Studies

Research has explored whether Ketasol-100 is related to clinical outcomes in pain management. Clinical trials investigated changes related to chronic low-back pain, with specific focus on patients presenting with neuropathic symptoms. Studies analyzed differences in pain scores, with research exploring whether changes in these scores occurred over observation periods, including intervals up to six months. Researchers also investigated patient-reported outcomes.

Studies examining the drug’s profile also included analysis of how administration methods influenced absorption. Furthermore, the comparison of outcomes against other treatments was investigated in some randomized studies to understand the relative observed effects of Ketasol-100 against established therapies.

---

Anxiety Management Research

Research consistently shows that studies examined differences in symptoms related to General Anxiety Disorder (GAD). A significant body of evidence, including meta-analyses, has examined whether the combination of Ketasol-100 and cognitive behavioral therapy (CBT) demonstrated an observed relationship with patient outcomes compared to CBT alone. The occurrence of adverse events with this combination was studied across multiple trial groups.

Investigational Use: Studies also examined the profile of this treatment in certain patient populations, such as those with severe liver impairment. Clinical data were also examined to assess observed differences in outcomes for conditions outside the primary indication, such as post-traumatic stress disorder (PTSD).

Key Studies & References Ketasol-100 in Generalized Anxiety Disorder (GAD): Phase 3 Results

Common questions about Ketasol-100 (FAQ)

Q: How quickly can a person expect Ketasol-100 to start having an effect?

According to official product information, Ketasol-100 is a rapid-acting medicine. The onset of the anesthetic effect when injected into a vein (IV) is usually observed within 30 seconds. When injected into a muscle (IM), the onset typically takes longer, usually appearing within 3 to 4 minutes.

---

Q: How long does the primary effect of one dose of Ketasol-100 typically last?

The primary anesthetic effect of one dose is relatively short, as detailed in regulatory documents. After an intravenous (IV) injection, the effect typically lasts between 5 and 10 minutes. Following an intramuscular (IM) injection, the effect is observed for a longer period, usually 12 to 25 minutes.

---

Q: Is Ketasol-100 designed for short-term treatment or is it usually taken long-term?

The labeled indication for Ketasol-100 is for use as an anesthetic agent for short-term diagnostic and surgical procedures. Regulatory warnings are noted regarding specific risks associated with prolonged or repeated exposure to the drug.

---

Q: What information is available regarding the use of Ketasol-100 by elderly patients?

According to the official product information for special populations, the dose is typically selected conservatively for elderly patients. The official guidance emphasizes a conservative starting point, primarily because of the greater frequency of decreased organ function in this population.

---

Q: Is Ketasol-100 known to affect a person's ability to drive or operate machinery?

Regulatory documents carry warnings that the effects of Ketasol-100 on the central nervous system may impair the ability to drive, operate machinery, or perform other hazardous tasks. This impairment may last for up to 24 hours after administration.

---

Q: Are changes in sleep patterns a commonly reported side effect of Ketasol-100?

Changes to consciousness, such as vivid dreams, are noted during the immediate recovery phase (emergence phenomena). However, changes to long-term sleep patterns are not explicitly listed in the official adverse reaction documentation.

---

Q: How common is it to feel unusually tired or drowsy when beginning Ketasol-100?

General feelings of tiredness or drowsiness are not typically listed as a common adverse reaction for Ketasol-100 itself. However, official information warns that co-administration with other Central Nervous System (CNS) depressants can result in profound sedation.

---

Q: What is known about the effects of stopping Ketasol-100 suddenly (discontinuation or withdrawal)?

Official documents describing the potential for abuse and dependence state that abrupt discontinuation following chronic use may lead to withdrawal symptoms. These symptoms may require management by a healthcare provider.

---

Q: Can Ketasol-100 be used by children or adolescents?

Regulatory documents describe that Ketasol-100 can be used in the pediatric population. However, an official warning is noted regarding potential long-term cognitive deficits from prolonged or repeated exposure in children 3 years of age or younger.

---

Q: Is Ketasol-100 known to be habit-forming or create physical dependence?

Official regulatory documents recognize the potential for abuse and subsequent psychological dependence with chronic, non-medical use. For this reason, the medicine is classified as a controlled substance.

---

Q: Why do some users report a 'foggy' feeling or difficulty concentrating on Ketasol-100?

The feelings of being 'foggy' or disoriented are likely related to the temporary emergence phenomena described in official labeling. These psychiatric effects can occur during recovery and include feelings of dissociation (feeling disconnected), delirium, and vivid dreams.

---

Q: What are the serious but rare side effects of Ketasol-100 that are described in official leaflets?

Official safety information classifies adverse events by frequency. Side effects classified as rare—meaning they may affect up to 1 in 1,000 patients—may include specific skin reactions or changes in eye pressure.

---

Q: What are the signs that Ketasol-100 may not be suitable for a person?

Regulatory documents state that Ketasol-100 is considered unsuitable for people with known hypersensitivity or those for whom a significant increase in blood pressure would be a serious hazard. This includes individuals with pre-existing conditions like severe hypertension or a history of stroke.

---

Q: Is Ketasol-100 used in emergency or acute care settings, according to its labeling?

Ketasol-100 is officially labeled for use as an anesthetic agent for diagnostic and surgical procedures. Its pharmacological profile often allows it to be used in acute care or emergency settings where maintaining cardiovascular function is important.

---

Q: Does having a history of kidney problems affect eligibility to use Ketasol-100?

According to official warnings, Ketasol-100 requires caution during administration to patients with severe renal impairment (kidney problems).

---

Q: What is the meaning or relevance of the number '100' in the drug name Ketasol-100?

Regulatory documents describe the product's highest concentration available in a single vial as 100 mg/mL. It is generally understood that the number in the brand name often reflects a key available strength or concentration.

---

Q: Are there different formulations or strengths of Ketasol-100 available?

Official regulatory documents list multiple available concentrations for the Ketasol-100 injection. These strengths include 10 mg/mL, 50 mg/mL, and 100 mg/mL solutions.

---

Q: What is the half-life of Ketasol-100 described as in official documents?

Pharmacokinetic data in the official documents describes the terminal elimination half-life of Ketasol-100. This is the time it takes for half of the drug to be eliminated from the body, which is approximately 2.5 to 3 hours in adults.

How to Store and Dispose of Ketasol-100?

Ketasol-100 (Ketamine Hydrochloride Injection) must be stored and disposed of according to strict official regulatory requirements to ensure product stability and safety as a controlled substance.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection	Store in the original container to protect from light, and the product must not be frozen.
Child Safety	Due to its controlled substance status, the medicine must be kept out of the sight and reach of children and secured in a locked area.
In-Use Stability	Any unused portion from a single-dose container must be discarded immediately.

Official Disposal Instructions

Disposal of unused or expired Ketasol-100 must align with federal and local regulations for controlled substances, typically requiring the use of official drug take-back programs. Used needles and syringes (sharps) must be placed directly into an FDA-cleared sharps disposal container. The medicine must not be disposed of into a household drain or wastewater system.